RNA-seq and miRNA-seq data from pharmacological inhibition of the G9a/GLP histone methyltransferase complex with UNC0642 in SAMP8 mice

Shrikant Pawar; Aina Bellver-Sanchis; Christian Griñán-Ferré

doi:10.1016/j.dib.2021.107114

RNA-seq and miRNA-seq data from pharmacological inhibition of the G9a/GLP histone methyltransferase complex with UNC0642 in SAMP8 mice

Data Brief. 2021 May 2:36:107114. doi: 10.1016/j.dib.2021.107114. eCollection 2021 Jun.

Authors

Shrikant Pawar¹, Aina Bellver-Sanchis², Christian Griñán-Ferré²

Affiliations

¹ Department of Genetics, Yale University, New Haven, CT, USA.
² Department of Pharmacology and Therapeutic Chemistry, Institut de Neurociències-Universitat de Barcelona, Avda. Joan XXIII, 27, Barcelona 08028, Spain.

Abstract

Growing evidence demonstrates the epigenetic modulation as a key event in Alzheimer's disease (AD) pathology. Furthermore, recent data suggests that the epigenetic regulation by the methyltransferase G9a is a crucial mechanism involved in learning and memory formation. Taking this into account, we hereby provide genomics data from pharmacological intervention with UNC0642, a potent and selective G9a/GLP in SAMP8 mice, a model of Alzheimer's disease (AD). We have generated novel RNA-seq and miRNA-seq data for three groups, healthy SAMR1, SAMP8 control and SAMP8 treated with UNC0642 (5 mg/Kg). Thus, the new data can be used to find miRNA regulation, and the mRNA's modified in AD under G9a/GLP inhibition.

Keywords: Alzheimer's disease; Epigenetics; G9a/GLP; RNA seq; SAMP8; SAMR1; UNC0642.